PT - JOURNAL ARTICLE AU - CHEN, PO-MING AU - HUANG, YU-HAN AU - CHEN, HSIN-HUNG AU - CHU, PEI-YI TI - Catalase Expression Is an Independent Prognostic Marker in Lung Adenocarcinoma AID - 10.21873/anticanres.16811 DP - 2024 Jan 01 TA - Anticancer Research PG - 287--300 VI - 44 IP - 1 4099 - http://ar.iiarjournals.org/content/44/1/287.short 4100 - http://ar.iiarjournals.org/content/44/1/287.full SO - Anticancer Res2024 Jan 01; 44 AB - Background/Aim: Lung adenocarcinoma (LUAD) is the deadliest cancer, and approximately 20% of stage I LUAD cases recur after surgical resection due to its high intratumor heterogeneity. Reactive oxygen species (ROS) have been detected in LUAD and are involved in carcinogenesis and tumor progression. Here, a comprehensive analysis was performed to evaluate the effects of antioxidants on the prognosis of LUAD. Materials and Methods: The Cancer Genome Atlas (TCGA) database was used to study the relationship of gene expression of different ROS-scavenging enzymes with the progression and prognosis of LUAD. Results: Using TCGA LUAD datasets, we found that catalase (CAT) expression was significantly down-regulated in LUAD tissues compared to normal tissues, CAT down-regulation differed significantly between different grades of LUAD, low CAT expression was independently correlated with a worse prognosis in LUAD, and the expression of the CAT gene was associated with an inhibition of the “cell cycle”. A panel of LUAD cells (CL1-0, CL1-1, CL1-3, and CL1-5), which harbored mutated p53 (R248W), with gradually increasing invasiveness showed a gradual decrease in CAT expression. Silencing of CAT upregulated cell growth in A549 cells, which harbor wild-type p53 and show high CAT expression and was associated with an increase in the expression of BUB1B, PLK1, and PKMYT1. Finally, over 38% (186/490) of LUAD cases with a p53 mutation exhibited significantly lower CAT expression than those with wild-type p53. Conclusion: CAT expression is a potent favorable prognostic marker for LUAD and may represent a drug target.